NICM
PCRX icon

Neo Ivy Capital Management’s Pacira BioSciences PCRX Stock Holding History

Neo Ivy Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-757
Closed -$44K – 504
2022
Q2 		$44K Buy
+757
New +$49.6K 0.12% 253

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Neo Ivy Capital Management's PCRX Position: Q3 2022 in Review

Neo Ivy Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 757 shares — an estimated $44K sold.

Neo Ivy Capital Management first reported a position in PCRX in Q2 2022 and held it in 1 quarter. The position peaked at $44K in Q2 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

  • Neo Ivy Capital Management reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
  • Neo Ivy Capital Management sold 757 Pacira BioSciences shares in Q3 2022, an estimated $44K.
  • Neo Ivy Capital Management first reported a position in Pacira BioSciences in Q2 2022 and held it in 1 quarter.
  • Neo Ivy Capital Management's Pacira BioSciences position peaked at $44K in Q2 2022.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Neo Ivy Capital Management's 13F filing for Q3 2022, filed 16 Nov 2022.